Table 1.
Model variables.
Figure 1.
Schematic representation of the discretized cell cycle model.
Figure 2.
Proliferation assay—Cell cycle distribution.
A) EdU positive population; B) EdU negative population.
Figure 3.
Proliferation assay—Proliferation marker Ki-67 and viability.
Figure 4.
Proliferation assay—Cyclin expression profiles.
A) Cyclin E1 expression—EdU positive cells, B) Cyclin E1 expression—EdU negative cells, C) Cyclin B1 expression—EdU positive cells, D) Cyclin B1 expression—EdU negative cells, E) Average cyclin E1 (for G1/G0 phase) and cyclin B1 (for G2/M) expression before and after glutamate exhaustion.
Figure 5.
Outputs: XV = viable cell density, fG1 = G1/G0 cell fraction, fS = S cell fraction, fG2 = G2/M cell fraction, and mAb = antibody titre.
Figure 6.
Modelling of control experiments.
A) Cell growth and viability, B) Glucose and lactate concentration profiles, C) Glutamate and mAb concentration profiles, D) Cell cycle distribution.
Figure 7.
Modelling of after thymidine arrest release experiment.
A) Cell growth and viability, B) Glucose and lactate concentration profiles, C) Glutamate and mAb concentration profiles, D) Cell cycle distribution.
Figure 8.
Modelling of after DMSO arrest release experiment.
A) Cell growth and viability, B) Glucose and lactate concentration profiles, C) Glutamate and mAb concentration profiles, D) Cell cycle distribution, E) Cell cycle distribution delay simulation. Grey lines: simulation with estimated parameters; Black lines: simulation with DMSO delay parameters (Table 2)
Table 2.
Model parameters values.
Figure 9.
Model prediction of an undisturbed cell cycle experiment.
A) Cell growth and viability, B) Glucose and lactate concentration profiles, C) Glutamate and mAb concentration profiles, D) Cell cycle distribution.